Highbridge Capital Management Acquires 7.1% Stake in Plus Therapeutics via Warrants

Highbridge Capital Management, LLC has filed a Schedule 13G reporting a new 7.1% stake in Plus Therapeutics, Inc. (PSTV) as of March 31, 2026. The reporting person disclosed beneficial ownership of 13,157,894 shares of common stock, which are issuable upon the exercise of warrants held by various Highbridge funds and accounts. Specifically, Highbridge Tactical Credit Master Fund, L.P. is identified as having the right to receive dividends or proceeds from more than 5% of the outstanding common stock. The calculation of the 7.1% ownership is based on 171,550,698 shares of common stock outstanding as of March 18, 2026, assuming the full exercise of the reported warrants. Highbridge Capital Management serves as the investment adviser to the funds holding these securities. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This filing marks a significant increase from a previous 0% ownership position.